|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0008059,
umls-concept:C0008109,
umls-concept:C0027819,
umls-concept:C0040732,
umls-concept:C0079460,
umls-concept:C0086418,
umls-concept:C0229601,
umls-concept:C0281581,
umls-concept:C0591833,
umls-concept:C0920321,
umls-concept:C1516476,
umls-concept:C2603343
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2001-1-18
|
|
pubmed:abstractText |
Ganglioside G(D2) is strongly expressed on the surface of human neuroblastoma cells. It has been shown that the chimeric human/murine anti-G(D2) monoclonal antibody (ch14.18) can induce lysis of neuroblastoma cells by antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The purposes of the study were (1) to determine the maximum-tolerated dose (MTD) of ch14.18 in combination with standard dose granulocyte-macrophage colony-stimulating factor (GM-CSF) for patients with neuroblastoma who recently completed hematopoietic stem-cell transplantation (HSCT), and (2) to determine the toxicities of ch14.18 with GM-CSF in this setting.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4077-85
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11118469-Adolescent,
pubmed-meshheading:11118469-Animals,
pubmed-meshheading:11118469-Antibodies, Monoclonal,
pubmed-meshheading:11118469-Antibody Formation,
pubmed-meshheading:11118469-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:11118469-Child,
pubmed-meshheading:11118469-Child, Preschool,
pubmed-meshheading:11118469-Combined Modality Therapy,
pubmed-meshheading:11118469-Disease Progression,
pubmed-meshheading:11118469-Dose-Response Relationship, Immunologic,
pubmed-meshheading:11118469-Drug Administration Schedule,
pubmed-meshheading:11118469-Female,
pubmed-meshheading:11118469-Follow-Up Studies,
pubmed-meshheading:11118469-Gangliosides,
pubmed-meshheading:11118469-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:11118469-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:11118469-Humans,
pubmed-meshheading:11118469-Male,
pubmed-meshheading:11118469-Mice,
pubmed-meshheading:11118469-Neuroblastoma,
pubmed-meshheading:11118469-Recombinant Fusion Proteins
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
|
|
pubmed:affiliation |
Department of Pediatrics, Section of Hematology/Oncology, New York Medical College, Valhalla, NY, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
